It was recently suggested that higher plasma levels of IL-1α and TGF-β and lower levels of IFN-β could point to a greater risk of changes similar to those observed in pulmonary fibrosis in patients after COVID-1917. This evidence concerns the gene IL1A and pulmonary fibrosis.